Tenax Therapeutics, Inc. (TENX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 1.78 |
| Open | 1.82 |
| Day High | 1.84 |
| Day Low | 1.73 |
| 52-Week High | 19.4 |
| 52-Week Low | 1.31 |
| Volume | 4.15M |
| Average Volume | 3.88M |
| Market Cap | 46.42M |
| PE | -1.18 |
| EPS | -1.48 |
| Moving Average 50 Days | 11.84 |
| Moving Average 200 Days | 12.14 |
| Change | -0.03 |
Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference
GlobeNewswire Inc.
Mar 03, 2026 12:00 PM GMT
CHAPEL HILL, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopul
Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026
GlobeNewswire Inc.
Feb 04, 2026 12:00 PM GMT
CHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulm
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
GlobeNewswire Inc.
Dec 17, 2025 2:16 PM GMT
Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2026 Global Phase 3 LEVEL-2 Study Initiated; Compan